Status:
RECRUITING
Emergency PWAS in Respiratory Infectious Disease
Lead Sponsor:
The University of Hong Kong
Conditions:
Viral Infections
Bacterial Infections
Eligibility:
All Genders
18-100 years
Brief Summary
Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenti...
Detailed Description
Introduction Pandemic Preparedness The COVID-19 pandemic has affected over 220 million people, claimed over 450 000 lives and invoked variable responses across the world. Delays in acquiring quality...
Eligibility Criteria
Inclusion
- Patients eligible for enrolment include:
- With reference to previous inclusion criteria are:
- Adults ≥18 years of age; AND
- Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\*; AND
- Informed consent.
- Note: scaRID is defined according to ALL three criteria:
- Community acquired (not hospitalised for \<28 days); AND
- Acute infection (defined as symptom onset \<8 days and any ONE of reported fever or chills or aural temperature \>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND
- Probable respiratory infection - According to any ONE of:
- new cough or new sputum production or
- chest pain or
- dyspnoea or
- tachypnoea or
- abnormal lung examination or
- respiratory failure; or
- physician's judgment (presenting with systemic or gastrointestinal symptoms).
- Control subjects will be drawn from two groups:
- The worried well - adult patients with a National Early Warning Score (NEWS) \<3 and a temperature \<37.5°C.
- Relatives or accompanying friends with no acute illness.
Exclusion
- Refusal of consent;
- Recent hospitalisation (\<28 days);
- Enrolled in another clinical trial
- Cellulitis;
- Skin or orthopaedic infections;
- Urinary tract infection;
- Acute abdominal sepsis;
- Sexual transmitted disease;
- Human immunodeficiency virus (HIV) infection;
- Immunocompromised/potential neutropenic fever;
- Solid organ or haematopoietic stem-cell transplant within the previous 90 days;
- Active graft-versus-host disease or bronchiolitis obliterans;
- Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases;
- Stroke;
- Toxidrome;
- Non-organic acute psychosis.
Key Trial Info
Start Date :
April 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05336851
Start Date
April 11 2023
End Date
May 1 2025
Last Update
May 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hong Kong University
Hong Kong, China